Hanxin Biotechnology

China-based gene therapy Contract Research Organization (CRO) OBiO Technology (Shanghai) Co., Ltd (SHA: 688238) has announced a partnership with compatriot firm Hanxin Biotechnology (Suzhou) Co., Ltd. The collaboration is focused on the lipid nanoparticle (LNP) delivery system field, aiming to enhance the clinical application of mRNA and other nucleic acid…